Implanted sensor continuously transmits blood glucose levels for insulin control
2 August 2010
A glucose sensor implanted under the skin that transmits glucose measurements continuously to an external device has been successfully tested for over 500 days, but only in a pig so far.
The external device shows current blood glucose level, a historical chart and adjustable warnings of high and low blood glucose readings.
The ultimate goal is to limit the dangerous ups and downs of blood glucose levels in diabetics, known as 'glucose excursions'. It is these prolonged glucose excursions that cause the long-term problems associated with diabetes. The implant used in the pig study is about 1.5" diameter and 5/8" thick, and could be implanted in a simple outpatient procedure.
The device was developed by engineers at the University of California, San Diego and GlySens Incorporated and the study of the device implanted in a pig was published in the July 28, 2010 issue of the journal Science Translational Medicine .
How the sensor works
Glucose and oxygen from the surrounding tissue diffuse to the sensor, where the enzyme glucose oxidase carries out a chemical reaction in which oxygen is consumed in proportion to how much glucose is present.
The remaining oxygen is measured and compared to the baseline oxygen recorded by a nearly identical oxygen reference sensor. The reduced oxygen signal compared to background oxygen signal reflects the glucose concentration.
The effects of exercise and changes in local blood flow to the tissues are also largely subtracted out by the differential oxygen sensing system, which includes the pair of sensors side by side in the same device. The implanted sensor sends the glucose information to a data recorder the size of a cell phone.
After human clinical trials and FDA approval, the device may be useful to people with diabetes as an alternative to finger sticking, and to short-term needle-like glucose sensors that have to be replaced every three to seven days.
David Gough, Professor of Bioengineering and the UC San Diego Jacobs School of Engineering, said, "The Science Translational Medicine paper shows our implanted sensors to be successful in animals. You can run the device for a year or more with it constantly working, and recording glucose quite satisfactorily. Now, we are focused on getting the human clinical trials going. We hope to begin the first human trial within in a few months. If all goes well with the human clinical trials we anticipate that in several years this device could be purchased under prescription from a physician."
"There are parents with diabetic children who spend their nights worrying that their child in a nearby bedroom may go into nocturnal hypoglycemia," said Gough, who explained that the glucose sensors could be used to send information to a phone that would alert parents if the child's glucose levels drop to a dangerous level during the night.
"Four finger sticks per day to measure glucose levels is the current standard of care, but blood glucose can go on significant excursions between sticks," said Gough. In contrast, the long-term implanted glucose monitor would provide continuous monitoring day and night. "We are moving toward something that will be automatic and quite unobtrusive. Others wouldn't even know if someone is using a glucose sensor. Our goal is to get people off the finger stick cycle," said Gough.
Suitable for Type 1 or Type 2 Diabetes
The long-term glucose sensor could be used by people with either Type 1 or Type 2 diabetes. People with Type 1 diabetes do not make enough insulin of their own. The long-term glucose sensors could be used to adjust the insulin dose and timing of the injection, and reduce the risk of taking too much insulin and becoming hypoglycaemic, which can be immediately life threatening. Hypoglycaemia happens when you get too much insulin for the available glucose, or when insulin absorbs too rapidly.
People with Type 2 diabetes could use the long-term glucose sensors to help them adjust their diet and exercise schedule. Also, some people with Type 2 diabetes take insulin and have the same hypoglycaemia worries as people with Type 1 diabetes.
Today, there are approximately 800,000 people using external insulin pumps in the US alone. Currently, these insulin pumps are open loop — meaning they are not connected to a glucose sensor directly, and they have to be programmed by a physician. "You can manually adjust the pump schedule to some extent, but patients must keep rigid schedules to live with an insulin pump," said Gough.
The bioengineers’ goal is to enable the pumps to automatically adjust the rate of insulin being administered based on glucose readings from the implanted sensors, that is, to function like an artificial pancreatic beta cell. "If insulin pumps were programmed based on near-real-time readings from implanted glucose sensors, the pumps would adjust insulin dosing based on what your glucose number is after a meal. You wouldn't have to be so rigorous about your schedule," said Gough.
"With an insulin pump, there is always the concern that it will pump too much insulin, leading to dangerously low blood glucose levels. The sensor could serve as a safety mechanism against low blood glucose levels," said Gough, who noted that major research efforts to use readings from glucose sensors to program insulin pumps are well underway. Researchers are primarily using needle-type glucose sensors, but these needle sensors could be replaced with the new implanted sensors if and when they are approved for human use.
1. David A. Gough, Lucas S. Kumosa, Timothy L. Routh, Joe T Lin and